TransCode Therapeutics Inc (RNAZ)
0.707
+0.08
(+12.26%)
USD |
NASDAQ |
May 02, 16:00
0.70
-0.01
(-0.99%)
Pre-Market: 08:30
TransCode Therapeutics Cash from Financing (TTM): 2.252M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.252M |
| September 30, 2023 | 19.45M |
| June 30, 2023 | 11.83M |
| March 31, 2023 | 5.475M |
| December 31, 2022 | 4.30M |
| September 30, 2022 | -23.87M |
| June 30, 2022 | 1.912M |
| Date | Value |
|---|---|
| March 31, 2022 | 1.991M |
| December 31, 2021 | 1.853M |
| September 30, 2021 | 25.49M |
| June 30, 2021 | -0.1262M |
| March 31, 2021 | -0.0151M |
| December 31, 2020 | 1.116M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-23.87M
Minimum
Sep 2022
25.49M
Maximum
Sep 2021
3.974M
Average
1.991M
Median
Mar 2022
Cash from Financing (TTM) Benchmarks
| Citius Pharmaceuticals Inc | -- |
| NovaBay Pharmaceuticals Inc | 1.91M |
| Palatin Technologies Inc | 5.553M |
| iBio Inc | 10.68M |
| Theriva Biologics Inc | 0.625M |